EUCTR2016-002621-10-GR进行中（未招募）1 期
A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed Written Informed Consent
- •- Histologically confirmed Stage 4 or recurrent non-small cell lung cancer
- •- Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out light housework or office work through to being fully active as you were before cancer) for cohort A, B and C
- •- No prior systemic anticancer therapy (including EGFR and ALK inhibitors) for cohort A, A1 and C
- •- Tissue or Programmed death-ligand 1 (PD-L1) results available
- •Cohort 1A Inclusion Criteria:
- •- Eastern Cooperative Oncology Group (ECOG) score 2 or
- •- Eastern Cooperative Oncology Group (ECOG) score 0-1 and one disease specific criteria as listed in the protocol
- •Cohort C Inclusion Criteria:
- •- High Tumor Mutation Burden
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1120
排除标准
- •- Untreated brain metastases
- •- An active malignancy that requires concurrent intervention
- •- Active, known or suspected autoimmune disease
- •- Carcinomatous meningitis, which means there is inflammation of the covering of the brain, caused by cancer
研究者
相似试验
进行中（未招募）
1 期
ivolumab and ipilimumab in combination for lung cancer.on-Small Cell Lung CancerMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002621-10-BEBristol-Myers Squibb International Corporation2,240
已完成
3 期
A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung CancerNon-small cell lung cancerNL-OMON47686Bristol-Myers Squibb22
进行中（未招募）
1 期
ivolumab and ipilimumab in combination for advanced malignancies.Advanced MalignanciesMedDRA version: 19.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2016-002621-10-FRBristol-Myers Squibb International Corporation500
进行中（未招募）
1 期
ivolumab and ipilimumab in combination for Lung Canceron-Small Cell Lung CancerMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002621-10-CZBristol-Myers Squibb International Corporation2,240
进行中（未招募）
1 期
ivolumab and ipilimumab in combination for advanced malignancies.EUCTR2016-002621-10-HUBristol-Myers Squibb International Corporation500